Quantitative Fetomaternal Hemorrhage Assessed with Lab Tests
By LabMedica International staff writers Posted on 06 Oct 2016 |

Image: The COULTER AcT diff2 hematology analyzer (Photo courtesy of Beckman Coulter).
Fetomaternal hemorrhage (FMH) assessment is usually used to determine anti-D immunoglobulin dose in postpartum prophylaxis of the hemolytic disease of the fetus and newborn (HDFN).
In maternal blood, fetal red blood cells (RBCs) can be identified due to the differences between them and adult RBCs and these are fetal hemoglobin (HbF) presence, lack of the carbonic anhydrase (CA), and the presence of particular group antigen.
Scientists at the Centre of Postgraduate Medical Education (Warsaw, Poland) collected blood samples on EDTA as follows: 20 RhD-negative blood donors samples to evaluate test specificity, 18 RhD-negative blood donors and 18 RhD-positive cord blood samples to prepare mixtures imitating FMH from 0.1% to 5%, and 14 weak D blood donors samples to evaluate test specificity with anti-D antibodies and to perform 20 suspensions with the RBCs of 10 RhD-positive blood donors. Blood samples from 98 women were tested: 74 from women just before labor and in 1 to 2 hours after it, 10 only before childbirth, including five before 40 weeks of pregnancy, due to fetal anemia, and 14 only after labor.
The amount and parameters of RBCs were measured with the COULTER AcT diff/diff2 Hematology Analyzer (Beckman Coulter, Brea, CA, USA) to prepare RBCs mixtures with the known percentage of fetal cells. The team used three flow cytometry methods including Antigen D staining, Hemoglobin F (HbF) staining and HbF and carbonic anhydrase (CA) staining. The flow cytometer was calibrated correctly and in all samples, 50,000 RBCs were analyzed using FACSCanto II and FACSDiva software (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The scientists also carried out Kleihauer–Betke test (KBT), which is based on HbF resistance to acid elution while HbA is removed from cells.
The hematologists found that in all artificial mixtures with known concentrations, FCTs and KBT with counting 10,000 RBCs had similar satisfying sensitivity and specificity. KBT with counting 2000 RBCs had to be disqualified because of significant discrepancies between expected and measured values of FMH. The test procedure with anti-D was easier and shorter than the remaining tests, but it can be only used for FMH assessment in RhD-negative mothers with RhD-positive newborns. In one clinical sample, it was impossible to distinguish fetal RBCs from maternal F cells in KBT and FC with anti-HbF but other tests were useful.
The authors concluded that the methods that use flow cytometry and anti-HbF, anti-D, and anti-HbF + anti-CA antibodies, as well as microscopic Kleihauer–Betke test detecting HbF-positive blood cells, with counting 10 000 of RBCs, have similar satisfying sensitivity and specificity. In the four tests, correlation between expected and obtained results was appropriate. Each test had some advantage and limitation in any clinical situation. Therefore, it is best to have opportunity to perform two or three assays in the laboratory. The study was published in the August 2016 issue of the International Journal of Laboratory Hematology.
Related Links:
Centre of Postgraduate Medical Education
Beckman Coulter
BD
In maternal blood, fetal red blood cells (RBCs) can be identified due to the differences between them and adult RBCs and these are fetal hemoglobin (HbF) presence, lack of the carbonic anhydrase (CA), and the presence of particular group antigen.
Scientists at the Centre of Postgraduate Medical Education (Warsaw, Poland) collected blood samples on EDTA as follows: 20 RhD-negative blood donors samples to evaluate test specificity, 18 RhD-negative blood donors and 18 RhD-positive cord blood samples to prepare mixtures imitating FMH from 0.1% to 5%, and 14 weak D blood donors samples to evaluate test specificity with anti-D antibodies and to perform 20 suspensions with the RBCs of 10 RhD-positive blood donors. Blood samples from 98 women were tested: 74 from women just before labor and in 1 to 2 hours after it, 10 only before childbirth, including five before 40 weeks of pregnancy, due to fetal anemia, and 14 only after labor.
The amount and parameters of RBCs were measured with the COULTER AcT diff/diff2 Hematology Analyzer (Beckman Coulter, Brea, CA, USA) to prepare RBCs mixtures with the known percentage of fetal cells. The team used three flow cytometry methods including Antigen D staining, Hemoglobin F (HbF) staining and HbF and carbonic anhydrase (CA) staining. The flow cytometer was calibrated correctly and in all samples, 50,000 RBCs were analyzed using FACSCanto II and FACSDiva software (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The scientists also carried out Kleihauer–Betke test (KBT), which is based on HbF resistance to acid elution while HbA is removed from cells.
The hematologists found that in all artificial mixtures with known concentrations, FCTs and KBT with counting 10,000 RBCs had similar satisfying sensitivity and specificity. KBT with counting 2000 RBCs had to be disqualified because of significant discrepancies between expected and measured values of FMH. The test procedure with anti-D was easier and shorter than the remaining tests, but it can be only used for FMH assessment in RhD-negative mothers with RhD-positive newborns. In one clinical sample, it was impossible to distinguish fetal RBCs from maternal F cells in KBT and FC with anti-HbF but other tests were useful.
The authors concluded that the methods that use flow cytometry and anti-HbF, anti-D, and anti-HbF + anti-CA antibodies, as well as microscopic Kleihauer–Betke test detecting HbF-positive blood cells, with counting 10 000 of RBCs, have similar satisfying sensitivity and specificity. In the four tests, correlation between expected and obtained results was appropriate. Each test had some advantage and limitation in any clinical situation. Therefore, it is best to have opportunity to perform two or three assays in the laboratory. The study was published in the August 2016 issue of the International Journal of Laboratory Hematology.
Related Links:
Centre of Postgraduate Medical Education
Beckman Coulter
BD
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more